RESUMEN
Objective:To explore the interventional effect of β-sitosterol on ovalbumin(OVA)-induced allergic asthma rats and its potential mechanism.Methods:SD male rats were randomly divided into normal group(CON),model group(M),positive drug dexamethasone group(DEX,0.075 mg/kg)and β-sitosterol group(Sit,50 mg/kg).A rat model of allergic asthma was estab-lished by intraperitoneal injection of OVA with aluminum hydrogen solution,and nebulized inhalation of OVA to stimulate.Rats were given intragastric administration 30 min before aerosol challenge,and after continuous administration for 7 days,the indicators of cough and asthma and tracheal phenol red excretion were detected.HE staining was used to observe pathological changes of lung tis-sue.Flow cytometry was used to detect reactive oxygen species(ROS)generation,apoptosis level and ratios of Th17 and Treg cells in peripheral blood.Biochemical method was used to detect contents of MDA,and activities of T-SOD and GSH-Px in rat lung tissues.ELISA was used to detect levels of Th17 and Treg-related cytokines(TNF-α,IL-4,IL-6,IL-17A,and IL-35).Results:Compared with model group,β-sitosterol significantly prolonged the incubation period of cough and gasp in rats with allergic asthma,reduced the frequency of cough and gasping,and promoted the excretion of phenol red in trachea;significantly reduced inflammatory infiltration in lung tissue of asthmatic rats;observably reduced MDA content in lung tissue,ROS of primary lung cell and apoptosis levels of asthmatic rats,increased the activities of T-SOD and GSH-Px;markedly reduced proportion of Th17 cells and levels of pro-inflammatory cyto-kines TNF-α,IL-4,IL-6 and IL-17A,increased proportion of Treg cells and levels of anti-inflammatory cytokine IL-35.Conclusion:β-sitosterol can ameliorate airway inflammation and oxidative damage in OVA-induced allergic asthmatic rats,and its mecha-nism may be related to the regulation of β-sitosterol on Th17/Treg immune imbalance and oxidative stress response.
RESUMEN
OBJECTIVE:To observe the efficacy and safety of proton pump inhibitors combined with Compound digestive en-zyme tablet in the treatment of epigastric pain syndrome with abdominal distension. METHODS:156 patients with epigastric pain syndrome with abdominal distension were randomly divided into control group(75 cases)and observation group(81 cases). Con-trol group was given 40 mg Esomeprazole enteric-coated tablet for once half an hour before breakfast;observation group was addi-tionally given 243.6 mg Compound digestive enzyme tablet immediately after meal,3 times a day. The treatment course for both groups was 2 weeks. Clinical efficacy,clinical symptom score,pepsinogenⅠ(PGⅠ),pepsinogenⅡ(PGⅡ),2,4 h postprandial gastric emptying rate before and after treatment,and incidence of adverse reactions in 2 groups were observed. RESULTS:The to-tal effective rate in observation group was significantly higher than control group,the difference was statistically significant (P0.05). Before treatment, there were no significant differences in the clinical symptom score,PGⅠ,PGⅡand 2,4 h postprandial gastric emptying rate(P>0.05). After treatment,clinical symptom score in 2 groups were significantly lower than before,and observation group was lower than control group;PGⅠ and PGⅡ in observation group were significantly higher than before and control group,the differences were statistically significant(P0.05). CONCLUSIONS:The efficacy of pro-ton pump inhibitors combined with Compound digestive enzyme tablet is superior to the proton pump inhibitors in the treatment of epigastric pain syndrome with abdominal distension,with similar safety.